Evidence map›Paper›PMID 38411062›Full record

ArticleAntimicrobial agents and chemotherapy2024

A Fabrice Somé, Melissa D Conrad, Zachari Kabré, Aminata Fofana, R Serge Yerbanga, Thomas Bazié, Catherine Neya, Myreille Somé, Tegawinde Josue Kagambega, Jenny Legac and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

A Fabrice SoméInstitut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.ORCID 0000-0002-1530-1493
Melissa D ConradDepartment of Medicine, University of California, San Francisco, California, USA.ORCID 0000-0002-9984-8030
Zachari KabréInstitut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.
Aminata FofanaInstitut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.
R Serge YerbangaInstitut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.
Thomas BaziéInstitut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.
Catherine NeyaInstitut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.
Myreille SoméInstitut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.
Tegawinde Josue KagambegaInstitut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.
Jenny LegacDepartment of Medicine, University of California, San Francisco, California, USA.
Shreeya GargDepartment of Medicine, University of California, San Francisco, California, USA.
Jeffrey A BaileyDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.
Jean-Bosco OuédraogoInstitut des Sciences et Techniques, Bobo-Dioulasso, Burkina Faso.
Philip J RosenthalDepartment of Medicine, University of California, San Francisco, California, USA.ORCID 0000-0002-7953-7622
Roland A CooperDepartment of Natural Sciences and Mathematics, Dominican University of California, San Rafael, California, USA.ORCID 0000-0002-8437-9382
Institut de Recherche en Sciences de la Santé · BFUniversity of California, San Francisco · USBrown University · USDominican University of California · US

Funding

Resistance of Malaria Parasites to Artemisinin-Based TherapiesR01AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2009 to 2024
$8.4M
Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipelineR01AI139179 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Philip Jon Rosenthal · 2018 to 2026
$6.3M
NIAID NIH HHS R01 AI075045NIAID NIH HHS R01 AI139179
6 · The paper itself

Abstract

Malaria remains a leading cause of morbidity and mortality in Burkina Faso, which utilizes artemether-lumefantrine as the principal therapy to treat uncomplicated malaria and seasonal malaria chemoprevention with monthly sulfadoxine-pyrimethamine plus amodiaquine in children during the transmission season. Monitoring the activities of available antimalarial drugs is a high priority. We assessed the

Indexed as

AntimalarialsFolic Acid AntagonistsMalariaMalaria, FalciparumArtemetherArtemether, Lumefantrine Drug CombinationBurkina FasoChildDrug CombinationsDrug ResistanceHumansLumefantrinePlasmodium falciparumPolymorphism, GeneticProtozoan ProteinsPyrimethamineAntimalarialsArtemetherArtemether, Lumefantrine Drug CombinationDrug CombinationsFolic Acid AntagonistsLumefantrineProtozoan ProteinsPyrimethamineantimalarial drugsBurkina Fasoex vivoPlasmodium falciparumsusceptibility

Identifiers

PMID38411062
PMCPMC10989024
OpenAlexW4392191498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.